Unmet Need Cardiovascular Therapeutics Market

Heart failure leads the indication category with 32.6% share in 2026, while gene therapy accounts for 44.4% of therapy type share. High-risk patients hold 47.8% of patient population share, supported by severe disease burden, measurable outcomes, targeted eligibility, and closer safety monitoring.